The week ahead – week 11

  • Heron Therapeutics updates on FDA acceptance of NDA for Cinvanti (HTX-019)
    Immunogen will present initial biomarker data from 20-patient biopsy cohort of Phase I trial of IMGN853 (mirvetuximab soravtansine)
  • Tesaro presents data from niraparib Phase 3 trial NOVA in patients with platinum-sensitive relapsed ovarian cancer at SGO
  • AstraZeneca presents Phase 3 data from SOLO 2 trial with olaparib in maintenance treatment for platinum-sensitive relapsed ovarian cancer patients
  • Advaxis presents OS data of initial cohort of Stage 2 of ADXS-HPV Phase 2 trial in metastatic cervical caner
  • Merck has a PDUFA date of Keytruda’s sBLA in relapsed/refractory classical Hodgkin lymphoma
  • Medicines Co presents full six-month and nine-month data from ORION-1 trial for lowering LDL cholesterol at ACC
  • Amgen presents late breaking data from Phase 2 outcomes trial FOURIER in combination with statin for secondary prevention in patients at high cardiovascular risk at ACC
  • Pfizer also presents late-breaking data on safety and efficacy of bococizumab from Phase 2 trials SPIRE-1 and SPIRE-2
  • Johnson & Johnson presents late-breaking data from Xarelto EINSTEIN CHOICE Phase 3 trial as well as from GEMINI ACS 1 trial
  • Amgen presents late-breaking date from evolocumab EBBINGHAUS study Phase 3 to evaluate cognitive function
  • Finally Boehringer Ingelheim presents late-breaking data from pradaxa RE-CIRCUIT Phase 3 trial in anticoagulant treatment in patients with atrial fibrillation

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s